Brasília – The new Executive Secretary of the Drug Market Regulation Chamber (Câmara de Regulação do Mercado de Medicamentos – CMED), Mateus Amâncio, stated that the forthcoming drug pricing resolution is “modern, balanced, and not a barrier to innovation.” The proposal, which received more than 1,400 contributions during public consultation, aims to replace rules in place since 2004 and adapt the regulatory framework to Brazil’s current pharmaceutical and biotechnology market.

Amâncio explained that the new text maintains CMED’s role in controlling medicine prices but incorporates technical and transparent criteria for evaluating innovative and high-cost products. The resolution seeks to increase predictability for the industry while ensuring equitable access for patients and fiscal sustainability for the Unified Health System (SUS).

He underscored that his administration will prioritize data-based regulation and continuous dialogue with all stakeholders, including the pharmaceutical industry, patient groups, and government bodies. Amâncio noted that CMED’s goal is to foster a regulatory environment that encourages innovation without compromising affordability.

In response to a question about the Brazilian Association of Drug Manufacturers (ABFMED), Amâncio revealed that a new complementary regulation will soon be released for public consultation, focusing on operational procedures and technical adjustments to improve transparency and regulatory efficiency. He said this measure will further clarify how price reviews and exceptional cases are handled, in line with the modernization effort.

Source: Futuro da Saúde

Want to explore this and other key issues in Brazil’s health system?
Contact us at pharmabrnews@gmail.com